Welcome!

News Feed Item

Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017

MISSION VIEJO, CA--(Marketwired - May 15, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2017.

The company reported net loss of $1,035,000 or $0.01 per share for the three months ended March 31, 2017. This compares to a net loss (before extraordinary items) of $629,000 or $0.01 per share for the three months ended March 31, 2016. The increase in net loss was primarily attributable to pre-IND work on AEOL 11114, the Company's compound in development for the treatment of Parkinson's disease and lower revenues from the Biomedical Advanced Research and Development Authority ("BARDA").

"During the quarter, we initiated a Phase 1 safety study of AEOL 10150 in healthy volunteers, completed manufacturing optimization and oral formulation development work on AEOL 11114 for Parkinson's disease, and reported positive results in an animal model of Cystic Fibrosis with inhaled AEOL 20415," stated John L. McManus, President and Chief Executive Officer. "Although we were disappointed with BARDA's notification in March that it had elected not to exercise additional options under the contract at this time, we are continuing work in process under the contract through its expiration in May 2019. In addition, we are submitting proposals to and have received indications of interest from other government agencies to expand the funding of AEOL 10150 as a medical countermeasure against the pulmonary effects of radiation exposure and sulfur mustard gas exposure."

Results of Operations for the Three Months Ended March 31, 2017

Revenue for the three months ended March 31, 2017 was $129,000, which compares to $565,000 for the three months ended March 31, 2016. The revenue is from the BARDA Contract and the decline in revenue is primarily attributable to a lower level of activity under that contract.

Research and Development ("R&D") expenses increased $93,000, or 19%, to $594,000 for the three months ended March 31, 2017 from $501,000 for the three months ended March 31, 2016. The increase is primarily attributable to manufacturing optimization and oral formulation development work for AEOL 11114.

General and administrative ("G&A") expenses decreased $123,000, or 18%, to $570,000 for the three months ended March 31, 2017 from $693,000 for the three months ended March 31, 2016. The decrease is primarily attributable to lower accounting and legal fees related to SEC filing requirements.

Results of Operations for the Six Months Ended March 31, 2017

Revenue for the six months ended March 31, 2017 was $212,000, which compares to $870,000 for the six months ended March 31, 2016. The revenue is from the BARDA Contract and the decline in revenue is primarily attributable to a lower level of activity under that contract.

Research and Development ("R&D") expenses increased $89,000, or 9%, to $1,082,000 for the six months ended March 31, 2017 from $993,000 for the six months ended March 31, 2016. The increase is primarily attributable to manufacturing optimization and oral formulation development work for AEOL 11114.

General and administrative ("G&A") expenses decreased $2,000 to $1,252,000 for the six months ended March 31, 2017 from $1,254,000 for the six months ended March 31, 2016. The decrease is primarily attributable to lower investor relations fees.

As of March 31, 2017, the Company had approximately $981,000 in cash and cash equivalents and 152,085,825 common shares outstanding. The Company had accounts receivable of $603,000 and accounts payable of $638,000 on March 31, 2017.

Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. Aeolus urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the Annual Report on Form 10-K are also available on the Company's website, at www.aolsrx.com.

About AEOL 10150

AEOL 10150 is a superoxide dismutase (SOD) mimic being developed for the treatment/mitigation of lung damage from exposure to chemical and radiological insults and to reduce/prevent lung damage in patients with Idiopathic Pulmonary Fibrosis (IPF) and in cancer patients receiving radiation therapy. AEOL 10150 protects tissue from damage and increases survival in animal models of lung damage after exposure to radiation toxic chemicals, agents that induce inflammation, and trauma by mitigating and/or preventing cell death, inflammation and fibrosis through its action on oxidative stress (Reactive Oxygen Species, or "ROS") and regulation of growth factors and chemokines including PTEN, TGF-β1, HIF-1α, TNF-α and IL-6, as well as impacting subsequent signaling pathways associated with ROS production, apoptosis and fibrosis such as NADPH-oxidase (Nox-4), PTEN, PI3K/p-Akt and p53/Bax. AEOL 10150 has been shown to improve survival and mitigate pulmonary damage in rodent models of SMG, chlorine gas and radiation exposure and in a nonhuman primate (NHP) model of whole thorax lung irradiation (WTLI). Given these promising results, Aeolus is developing AEOL10150 for the mitigation and/or treatment of pulmonary injury resulting from SMG exposure.

AEOL 10150 has performed well in animal safety studies, was well tolerated in two human clinical trials and is currently being tested in a third human study. Aeolus has received "Orphan Drug" designation for use in treating Lung ARS, Idiopathic Pulmonary Fibrosis and Amyotrophic Lateral Sclerosis and has active IND's for the Lung ARS and ALS indications. Preparations are currently underway to make IND filings for Idiopathic Pulmonary Fibrosis, Cancer Radiation Therapy and Pulmonary Effects of Sulfur Mustard Gas Exposure.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a platform of novel compounds, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed for the treatment of Idiopathic Pulmonary Fibrosis and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. These development efforts have been aided by substantial funding for toxicology, manufacturing, and preclinical and clinical studies from the US Department of Health and Human Services, for the development of AEOL 10150 as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the pulmonary effects of radiation exposure and sulfur mustard gas exposure. The Company is also developing AEOL 11114 as a treatment for Parkinson's Disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at www.aolsrx.com.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, a potential phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
                   CONDENSED CONSOLIDATED BALANCE SHEETS                    
                                 (Unaudited)                                
               (In thousands, except share and per share data)              
                                                                            
                                                    March 31,    September  
                                                       2017       30, 2016  
                                                   ------------ ------------
                      ASSETS                                                
Current assets:                                                             
  Cash and cash equivalents                        $       981  $     3,155 
  Accounts receivable                                      603          750 
  Prepaid expenses and other current assets                149          230 
                                                   ------------ ------------
    Total current assets                                 1,733        4,135 
                                                                            
Investment in CPEC LLC                                      32           32 
                                                   ------------ ------------
    Total assets                                   $     1,765  $     4,167 
                                                   ============ ============
                                                                            
  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                            
Current liabilities:                                                        
  Accounts payable and accrued expenses            $       638  $       972 
                                                   ------------ ------------
    Total current liabilities                              638          972 
                                                                            
                                                   ------------ ------------
    Total liabilities                                      638          972 
                                                                            
Commitments and Contingencies (Note H)                                      
                                                                            
Stockholders' equity:                                                       
  Preferred stock, $.01 par value per share,                                
   10,000,000 shares authorized:                                            
  Series A nonredeemable convertible preferred                              
   stock, 1,250,000 shares authorized as of March                           
   31, 2017 and September 30, 2016, respectively;                           
   no shares issued and outstanding as of March                             
   31, 2017 and September 30, 2016                           -            - 
  Series B nonredeemable convertible preferred                              
   stock, 1,600,000 and 1,600,000 shares                                    
   authorized as of March 31, 2017 and September                            
   30, 2016, respectively; 526,080 and 526,080                              
   shares issued and outstanding as of March 31,                            
   2017 and September 30, 2016                               -            - 
  Series C nonredeemable convertible preferred                              
   stock, 5,000 and zero shares authorized as of                            
   March 31, 2017 and September 30, 2016,                                   
   respectively; 4,500 and zero shares issued and                           
   outstanding as of March 31, 2017 and September                           
   30, 2016                                                  -            - 
  Common stock, $.01 par value per share,                                   
   200,000,000 shares authorized; 152,085,825                               
   shares issued and outstanding as of March 31,                            
   2017 and September 30, 2016                           1,520        1,520 
  Additional paid-in capital                           191,917      191,863 
  Accumulated deficit                                 (192,310)    (190,188)
                                                   ------------ ------------
    Total stockholders' equity (deficit)                 1,127        3,195 
                                                   ------------ ------------
    Total liabilities and stockholders' equity                              
     (deficit)                                     $     1,765  $     4,167 
                                                   ============ ============
                                                                            
                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
                                (Unaudited)                                 
                    (In thousands, except per share data)                   
                                                                            
                                     Three months Ended   Six Months Ended  
                                          March 31,           March 31,     
                                     ------------------- -------------------
                                       2017      2016      2017      2016   
                                     --------- --------- --------- ---------
Revenue:                                                                    
 Contract revenue                    $    129  $    565  $    212  $    870 
                                                                            
Costs and expenses:                                                         
 Research and development                 594       501     1,082       993 
 General and administrative               570       693     1,252     1,254 
                                     --------- --------- --------- ---------
  Total costs and expenses              1,164     1,194     2,334     2,247 
                                     --------- --------- --------- ---------
Loss from operations                   (1,035)     (629)   (2,122)   (1,377)
                                                                            
Interest expense                            -         -         -      (285)
                                     --------- --------- --------- ---------
Net loss                               (1,035)     (629)   (2,122)   (1,662)
Deemed dividend on Series C                                                 
 preferred stock                            -     1,906         -     2,486 
                                     --------- --------- --------- ---------
Net loss attributable to common                                             
 stockholders                        $ (1,035) $ (2,535) $ (2,122) $ (4,148)
                                     ========= ========= ========= =========
                                                                            
Net loss per weighted share                                                 
 attributable to common                                                     
 stockholders:                                                              
 Basic (Note E)                      $  (0.01) $  (0.02) $  (0.01) $  (0.03)
                                     ========= ========= ========= =========
 Diluted (Note E)                    $  (0.01) $  (0.02) $  (0.01) $  (0.03)
                                     ========= ========= ========= =========
                                                                            
Weighted average common shares                                              
 outstanding:                                                               
 Basic                                152,085   151,560   152,085   145,466 
                                     ========= ========= ========= =========
 Diluted                              152,085   151,560   152,085   145,466 
                                     ========= ========= ========= =========
                                                                            
                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS               
                                 (Unaudited)                                
                               (In thousands)                               
                                                                            
                                                         Six Months Ended   
                                                             March 31,      
                                                       ---------------------
                                                          2017       2016   
                                                       ---------- ----------
Cash flows from operating activities:                                       
  Net loss                                             $  (2,122) $  (1,662)
  Adjustments to reconcile net loss to net cash used                        
   in operating activities:                                                 
    Amortization of discount on note payable to                             
     shareholders                                              -        273 
    Accrued interest                                           -         12 
    Non-cash compensation                                     54         74 
    Change in assets and liabilities:                                       
      Accounts receivable                                    147        219 
      Deferred subcontractor cost                              -       (176)
      Prepaid expenses and other current assets               81       (111)
      Accounts payable and accrued expenses                 (334)      (567)
      Deferred revenue                                         -        183 
                                                       ---------- ----------
Net cash used in operating activities                     (2,174)    (1,755)
                                                                            
Cash flows from financing activities:                                       
Proceeds from issuance of common stock and common                           
 stock warrants, net                                           -      2,005 
Proceeds from issuance of preferred stock and common                        
 stock warrants, net                                           -      4,165 
                                                       ---------- ----------
Net cash provided by financing activities                      -      6,170 
Net increase (decrease) in cash and cash equivalents      (2,174)     4,415 
Cash and cash equivalents at beginning of period           3,155         94 
                                                       ---------- ----------
Cash and cash equivalents at end of period             $     981  $   4,509 
                                                       ========== ==========
                                                                            
Supplemental disclosure of non-cash financing                               
 activities:                                                                
Conversion of note payable to shareholders for common                       
 stock and warrants                                    $       -  $   1,000 
Conversion of accrued interest on note payable to                           
 shareholders for common stock and warrants            $       -  $      12 
Issuance of warrants for financing costs               $       -  $     266 
Deemed dividend on Series C preferred stock            $       -  $   2,486 
                                                                            

Contact:
John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9825

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.